Skip to main
LYEL
LYEL logo

Lyell Immunopharma (LYEL) Stock Forecast & Price Target

Lyell Immunopharma (LYEL) Analyst Ratings

Based on 2 analyst ratings
Strong Buy
Strong Buy 100%
Buy 0%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Lyell Immunopharma Inc. reported a strong cash position with cash, cash equivalents, and marketable securities totaling $320 million, reflecting a positive increase primarily due to a recent private placement. The company’s focus on solid tumors through innovative T-cell reprogramming technologies, combined with encouraging data from its product candidates like LYL797 and LYL273, suggests a significant growth opportunity in the CAR-T market and beyond. While challenges such as potential dilution and the need for stronger efficacy data remain, the overall financial health and emerging data support a favorable outlook for future advancements in their clinical pipeline.

Bears say

Lyell Immunopharma experienced a decrease in research and development expenses, dropping from $34.9 million in the second quarter to $28.2 million in the third quarter of 2025. Despite this reduction, the company lacks sufficient evidence to demonstrate the durability of its treatments and the effective management of toxicity, which raises concerns regarding their clinical viability. The limitations in sample size and follow-up for LYL273 hinder a reliable assessment of its durability and toxicity mitigation, contributing to an overall negative outlook on the company’s prospects.

Lyell Immunopharma (LYEL) has been analyzed by 2 analysts, with a consensus rating of Strong Buy. 100% of analysts recommend a Strong Buy, 0% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Lyell Immunopharma and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Lyell Immunopharma (LYEL) Forecast

Analysts have given Lyell Immunopharma (LYEL) a Strong Buy based on their latest research and market trends.

According to 2 analysts, Lyell Immunopharma (LYEL) has a Strong Buy consensus rating as of Dec 13, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $32.50, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $32.50, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Lyell Immunopharma (LYEL)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.